SC
EWTX icon

Stempoint Capital’s Edgewise Therapeutics EWTX Stock Holding History

Stempoint Capital’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-290,864
Closed -$9.16M – 93
2026
Q1 		$9.16M Sell
290,864
-70,012
-19% -$2.02M 1.75% 19
2025
Q4 		$8.96M Buy
+360,876
New +$7.24M 1.54% 20
2025
Q2 		– Sell
-180,255
Closed -$3.97M – 64
2025
Q1 		$3.97M Buy
180,255
+47,549
+36% +$1.25M 1.26% 28
2024
Q4 		$3.54M Buy
132,706
+112,806
+567% +$3.59M 0.88% 36
2024
Q3 		$531K Sell
19,900
-251,157
-93% -$5M 0.16% 50
2024
Q2 		$4.88M Buy
+271,057
New +$4.73M 1.43% 24

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Stempoint Capital's EWTX Position: Q2 2026 in Review

Stempoint Capital sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 290,864 shares — an estimated $9.16M sold.

Stempoint Capital first reported a position in EWTX in Q2 2024 and held it in 6 quarters. The position peaked at $9.16M in Q1 2026. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Stempoint Capital reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Stempoint Capital sold 290,864 Edgewise Therapeutics shares in Q2 2026, an estimated $9.16M.
  • Stempoint Capital first reported a position in Edgewise Therapeutics in Q2 2024 and held it in 6 quarters.
  • Stempoint Capital's Edgewise Therapeutics position peaked at $9.16M in Q1 2026.
  • 227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.